Glycemic control in the clinical management of diabetic patients

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 4, 2013, Pages 753-766

  Mosca, Andrea ^a   Lapolla, Annunziata ^b   Gillery, Philippe ^c  

^a Dipartimento Fisiopatologia Medico Chirurgica e Dei Trapianti   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c AMERICAN MEMORIAL HOSPITAL   (France)

Author keywords

Glycated albumin; Glycated hemoglobin; Glycation gap; HbA 1c glucose variability; Standardization

Indexed keywords

GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C;

AGE; ARTICLE; BODY MASS; CALIBRATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; DIABETIC PATIENT; DIET RESTRICTION; ETHNICITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE;

ACCREDITATION; AGE FACTORS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LABORATORIES; LABORATORY PERSONNEL; POINT-OF-CARE SYSTEMS; QUALITY ASSURANCE, HEALTH CARE; RISK FACTORS;

EID: 84882276716     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0594     Document Type: Article

References (97)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
2. American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes Care 2010;33(Suppl 1):62-9.
3. The International Expert Committee. International Expert Committee report on the role of the A 1c assay in the diagnosis of diabetes. Diabetes Care 2009;33:1327-34.
4. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13 (Suppl 1):1-68.
5. International Diabetes Federation. Global Guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005.
6. John WG. Haemoglobin A1c: analysis and standardization. Clin Chem Lab Med 2003;41:1199-212.
7. Little RR, Rohlfing CL, Sacks DB. National Glycohemoglobin Standardization Program (NGSP) Steering Committee. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011;57:205-14.
8. Lapolla A, Mosca A, Fedele D. The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr Metab Cardiovasc Dis 2011;21:467-75.
9. Elder C, Hinchliffe C, Wright N. HbA1c league tables: might assay variability encourage foul play? J Clin Pathol 2010;63:660.
10. Lenters-Westra E, Weykamp C, Schindhelm RK, Siebelder C, Bilo HJ, Slingerland RJ. One in five laboratories using various hemoglobin A1c methods do not meet the criteria for optimal diabetes care management. Diabetes Technol Therap 2011;13:1-4.
11. Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted performance criteria. Clin Chem 2010;56:44-52.
12. Matteucci E, Giampietro O. Point-of-care testing in diabetes care. Mini-reviews in Medicinal Chemistry 2011;11:1-7.
13. Kaiser P, Reinauer H. Diabetes melllitus: the long way of standardization of HbA 1c to the level of highest metrological order. Ger Med Sci 2011;9:1-4.
14. Panteghini M. Traceability as a unique tool to improve standardization in laboratory medicine. Clin Biochem 2009;42:236-40.
15. Panteghini M. Application of traceability concepts to analytical quality control may reconcile total error with uncertainty of measurement. Clin Chem Lab Med 2010;48:7-10.
16. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, et al. Global standardization of glycated hemoglobin measurement: the position of the IFCC working group. Clin Chem Lab Med 2007;45:1077-80.
17. Finke A., Kobold U, Hoelzel W, Weykamp C, Jeppsson JO, Miedema K. Preparation of a candidate primary reference material for the international standardisation of HbA 1c determinations. Clin Chem Lab Med 1998;36:299-308.
18. Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, et al. Approved IFCC reference method for the measurement of HbA 1c in human blood. Clin Chem Lab Med 2002;40:78-89.
19. Weykamp C, John WG, Mosca A, Hoshino T, Little R, Jeppsson JO, et al. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 2008;54:240-8.
20. IFCC. Available from: http://www.ifcchba1c.com/. Accessed on 24 November, 2012.
21. Hoelzel A, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC reference system for measurement of hemoglobin A 1c in human blood and the National Standardization Schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-74.
22. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007;30:2399-400.
23. Hanas R, John G. on behalf of the International HbA1c Consensus Committee. 2010 consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Clin Chem 2010;56:1362-4.
24. Panteghini M, John WG, Mosca A, Weykamp C. IFCC Report. Implementation of standardization of HbA1c measurement. Clin Chem Lab Med 2008;46:573-4.
25. Mosca A, Branca MT, Carta M, Genna ML, Giorda CB, Ghidelli R, et al. Recommendations for the implementation of international standardization of glycated hemoglobin in Italy. Clin Chem Lab Med 2010;48:623-6.
26. Braga F, Dolci A, Montagnana M, Pagani F, Paleari R, Guidi GC, et al. Revaluation of biological variation of glycated hemoglobin (HbA1c) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clin Chim Acta 2011;412:1412-6.
27. Weykamp CW, Mosca A, Gillery P, Panteghini M. The analytical goals for hemoglobin A1c measurement in IFCC units and National Glycohemoglobin Standardization Program units are different. Clin Chem 2011;57:1204-6.
28. Mosca A. Some practical advice on how to implement the international standardization of glycated hemoglobin measurement in Italy [Italian]. Biochimica Clinica 2011;35:36-41.
29. IFCC. Available from: http://www.ifcc.org/ifcc-executive-boardand- council/eb-task-forces/task-force-hba1c/. Access verified on 24 November, 2012.
30. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
31. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA 1c . Diabetes Care 2002;25:275-8.
32. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, for the A1c-derived average glucose (AFAG) study group. Translating the A1c assay into estimated average glucose values. Diabetes Care 2008;31:1-6.
33. Westgard QC. Available from: http://www.westgard.com/biodatabase1.htm. Accessed on 24 November, 2012.
34. Cohen RM, Franco RS, Khera PK, Smith EP, Lindseell CJ, Ciraolo PJ, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008;112:4284-90.
35. Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, et al. Evidence for interindividual hetereogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 2008;57:2445-52.
36. Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis, MO: Elsevier Saunders, 2012.
37. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1):S11-61.
38. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman S, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2011;57:e1- 47.
39. Mosca A, Paleari R, Mad è A, Ferrero C, Locatelli M, Ceriotti F. Commutability of control materials in glycohemoglobin determinations. Clin Chem 1998;44:632-8.
40. O ' Connor C, O ' Shea PM, Owens LA, Carmody L, Avalos G, Nestor L, et al. Trimester-specific reference intervals for haemoglobin A1c (HbA1c) in pregnancy. Clin Chem Lab Med 2012;50:905-9.
41. BIPM. Available from: http://www.bipm.org/jctlm. Accessed on 24 November, 2012.
42. Ponzo P, Dolci A, Scapellato L, Milano M, Paleari R, Mosca A, et al. Evaluation of commutability for Cobas Integra analytical system of the EQA materials for hemoglobin A 1c . Biochimica Clinica 2008;32:44-7.
43. Menchine MD, Arora S, Camargo CA, Ginde AA. Prevalence of undiagnosed and suboptimally controlled diabetes by point-ofcare HbA1c in unselected emergency department patients. Acad Emerg Med 2011;18:1-4.
44. Silverman RA, Thakker U, Ellman T, Wong I, Smith K, Ito K, et al. Hemoglobin A 1c as a screen for previously undiagnosed prediabetes and diabetes in an acute-care setting. Diabetes Care 2011;34:1908-12.
45. Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J. Performance of A 1C for the classification and prediction of diabetes. Diabetes Care 2011;34:84-9.
46. Van ' t Riet E, Alssema M, Rijkelijkhizen JM, Kostense PJ, Nijpels G, Dekker JM. Relationship between A 1c and glucose levels in the general Dutch population. Diabetes Care 2010;33:61-6.
47. Cavagnolli G, Comerlato J, Comerlato C, Renz PB, Gross JL, Camargo JL. HbA 1c measurement for the diagnosis of diabetes: is it enough? Diab Med 2011;28:31-55.
48. Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, et al. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 2010;47:231-6.
49. Zhou X, Pang Z, Gao W, Wang S, Zhang L, Ning F, et al. Performance of HbA1c and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by OGTT in Qingdao China. Diabetes Care 2010;33:545-50.
50. Mostafa SA, Davies MJ, Webb D, Gray LJ, Srinivasan BT, Jarvis J, et al. The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting type 2 diabetes mellitus. Diabetes Med 2010;27:762-9.
51. Carson AP, Reynolds K, Fonseca V, Muntner P. Comparison of A1C and fasting glucose criteria to diagnose diabetes among US adults. Diabetes Care 2010;33:95-7.
52. Chapp-Jumbo E, Edeoga C, Wang J, Dagogo-Jack S. Ethnic disparity in hemoglobin A1c levels among normoglycemic offspring of parents with type 2 diabetes. Endocr Pract 2011;2:1-18.
53. Marini MA, Succurro E, Arturi F, Ruffo MF, Andreozzi F, Sciacqua A, et al. Comparison of A 1c , fasting and 2-h post-load plasma glucose criteria to diagnose diabetes in Italian Caucasians. Nutr Metab Cardiovasc Dis 2012;22:561-6.
54. Zemlin AE, Matsha TE, Hassan MS, Erasmus RT. HbA1c of 6.5% to diagnose diabetes mellitus-does it work for us? The Bellville South Africa Study. PLoS One 2011;6:e22558.
55. Christensen DL, Witte DR, Kaduka L, Jorgensen ME, Borch- Johnsen K, Mohan V, et al. Moving to an HbA1c-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010;33:580-2.
56. Cowie C, Rust K, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of diabetes and risk for diabetes using hemoglobin A1c criteria in the US population in 1998-2006. Diabetes Care 2010;33:562-8.
57. Lipska KJ, De Rekeneire N, Van Ness PH, Johnson KC, Kanaya A, Koster A, et al. Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A 1c . J Clin Endocrin Metab 2010;95:5289-95.
58. Tay TL, Foo JP, Tan E, Chen R, Khoo J, Soh SB, et al. HbA 1c may not be a sensitive determinant of diabetic status in the elderly. Diab Res Clin Pract 2011;92:e31-3.
59. Boronat M, Saavedra P, López-Rìos L, Riaño M, Wägner AM, Nóvoa FJ. Differences in cardiovascular risk profile of diabetic subjects discordantly classified by diagnostic criteria based on glycated hemoglobin and oral glucose tolerance test. Diabetes Care 2010;33:2671-3.
60. Selvin E, Steffes MW, Zhu H, Matsuhira K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in non-diabetic adults. N Engl J Med 2010;362:800-11.
61. Doerr R, Hoffmann U, Otter W, Heinemann L, Hunger-Battefeld W, Kulzer B, et al. Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography; the Silent Diabetes Study. Diabetologia 2011;54:2923-30.
62. Sturm G, Lamina C, Zitt E, Lhotta K, Haider F, Neyer U, et al. Association of HbA1c values with mortality and cardiovascular events in diabetic dialysis patients. The INVOR studies and review of the literature. PLoS One 2011;6:e20093.
63. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (Position Statement). Diabetes Care 2002;25:750-86.
64. Monnier L, Lapinski H, Colette C. Contribution of fasting and postprandial glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-5.
65. UK Prospective Diabetes Study group: intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patient with type 2 diabetes. Lancet 1998;352:837-53.
66. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. For the DCCT/EDIC Research Group: effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-Revisited. Diabetes 2008;57:995-1001.
67. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
68. Wax J. Metabolic memory: a vascular perspective. Cardiovasc Diabetol 2010;9:51.
69. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008;7:29.
70. Monnier L, Colette C. Target for glycemic control. Diabetes Care 2009;2:S199-204.
71. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-9.
72. Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan D, Heine RJ, et al. Associations between features of glucose exposure and HbA1c. The A1c-Derived Average Glucose (ADAG) study. Diabetes 2010;59:1585-90.
73. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implication of the ACCORD, ADVANCE and VA diabetes trials. Circulation 2009;119:1-7.
74. Ceriello A. The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract 2010;64:1705-11.
75. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-81.
76. Brownlee M, Hirsch IB. Glycemic variability: a haemoglobin A1c-independent risk factor for diabetic complications. J Am Med Assoc 2006;295:1707-8.
77. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 2006;295:1681-7.
78. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-54.
79. Kilpatrick ES, Rigby AS, Atkin SL. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patient with type 1 diabetes. Diabetologia 2008;51:365-71.
80. Kovatchev BP, Cox DJ, Farhy LS, Straume M, Gonder-Frederick L, Clarke WL. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab 2000;85:4287-92.
81. Kudva YC, Basu A, Jenkins GD, Pons GM, Vogelsang DA, Rizza RA, et al. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin. Endocr Pract 2007;13:244-50.
82. Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005;28:1231-9.
83. Sartore G, Chilelli NC, Burlina S, Di Stefano P, Piarulli F, Fedele D, et al. The importance of HbA 1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetol 2012. DOI: 10.1007/s00592- 012-0391-4.
84. Paroni R, Ceriotti F, Galanello R, Leoni GB, Panico A, Scurati E, et al. Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem 2007;40:1398-405.
85. Cohen RM, Chener TC, Holmes YR, Joiner CH. Discordance between HbA 1c and fructosamine. Diabetes Care 2003;26:163-7.
86. Cohen RM, Snieder H, Lindsell CJ, Beyan H, Harva MI, Blinko S, et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 2006;29:1739-43.
87. Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 2009;3:635-43.
88. Koga M, Kasayama S, Kanehara H, Bando Y. CLD (chronic liver disease)-HbA 1c as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver disease. Diabet Res Clin Pract 2008;81:258-62.
89. Bogner HR, Miller SD, De Vries HF, Chhatre S, Jayadevappa R. Assessment of cost and health resource utilization for elderly patients with heart failure and diabetes mellitus. J Card Fail 2010;16:454-60.
90. Sun Y, Toh MP. Impact of diabetes mellitus (DM) on the health-care utilization and clinical outcomes of patients with stroke in Singapore. Value Health 2009;12:S101-5.
91. Nuckols TK, McGlynn EA, Adams J, Lai J, Go MH, Keesey J, et al. Cost implications to health care payers of improving glucose management among adults with type 2 diabetes. Health Serv Res 2011;46:1158-79.
92. Dall TM, Roary M, Yang W, Zhang S, Chen YJ, Arday DR, et al. Health care use and costs for participants in a diabetes disease management program, United States, 2007-2008. Prev Chronic Dis 2011;8:A53.
93. Driskell OJ, Holland D, Hanna FW, Jones PW, Pemberton RJ, Tran M, et al. Inappropriate requesting of glycated hemoglobin (HbA 1c ) is widespread: assessment of prevalence, impact of national guidance, and practice-to-practice variability. Clin Chem 2012;58:906-15.
94. Aagren M, Luo W. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States. J Med Econ 2011;14:108-14.
95. Leach MJ, Segal L. Are clinical practical guidelines (CPGs) useful for health services and health work force planning? A critique of diabetes CPGs. Diabet Med 2010;27:570-7.
96. Katon J, Williams MA, Reiber G, Miller E. Antepartum A1c, maternal diabetes outcomes, and selected offspring outcomes: an epidemiological review. Paediatr Perinat Epidemiol 2011;25:265-76.
97. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-53